Decipher Plus — Top-Up the Gaps, Then Interpret
Test only what's missing. Combine with your existing data. Receive a signed Blueprint Care plan.
Decipher Plus is for when your existing report is almost enough. Rather than re-run everything, we test only the missing pieces — for example TMB, MSI, or pharmacogenomics — then combine the top-up with your existing data to produce a complete Blueprint Care decision. You pay for the gap, not the whole test again.
What Decipher Plus gives you
A complete Blueprint Care report — ranked decision, trial matches, biosimilar mapping, resistance plan, hereditary flags, and regional-language summary — built on your existing data plus only the missing pieces.
- Gap analysis: We identify exactly what's missing for a complete plan
- Targeted top-up: Only the missing markers are tested — nothing redundant
- Merge & interpret: Top-up and existing data combined through the engine
- KPCIRC sign-out: Licensed clinicians author the final plan
- Regional-language summary & navigator: Walked with you every step
Two reasons to choose Decipher Plus.
Your existing report is almost complete — we just need to fill the gaps.
Missing Immune Markers
Your report has drivers but no immune-related markers (TMB/MSI). We test just those markers and combine them with your existing data.
Missing Safety Markers
Pharmacogenomics or other markers needed for a safe, complete plan are absent. We top-up only what's needed.
Four steps to a complete decision.
From gap analysis to signed plan — no wasted testing.
Gap Analysis
We identify exactly what is missing for a complete plan.
Targeted Top-Up
Only the missing markers are tested — nothing redundant.
Merge & Interpret
Top-up and existing data are combined and run through the OnKommon Interpretation Engine.
KPCIRC Sign-Out
A full, signed Blueprint Care decision — with regional-language summary and navigator support.
Pay for the gap, not the whole test again.
Re-testing what you already have is waste. Decipher Plus respects the investment you have made and adds only what is genuinely needed — which is both cheaper and faster.
You've already paid for most of the picture. Decipher Plus fills only the missing pieces — no redundant testing, no wasted spend. You get a complete Blueprint Care decision for less than a full re-test.
A complete Blueprint Care report.
Everything you would get from a fresh Signature test — built on your existing data plus only the missing pieces.
Complete Blueprint Care Report
Ranked decision, contraindications, trials, biosimilars, resistance and monitoring plan, hereditary flags, pharmacogenomics, and access.
Regional-Language Summary
A plain-language version of your report, written for you and your family in the language you are most comfortable with.
Navigator Support
A dedicated coordinator walks you through results, access, and next steps — so you never have to navigate it alone.
Begin Decipher Plus
Send us your existing genomic report. We'll identify what's missing, test only those markers, and return a complete, signed Blueprint Care decision.
Submit Your Report for Decipher PlusWe'll assess your report and confirm the targeted top-up needed.
Decipher Plus is a genomic (DNA-based) test offered for use by qualified healthcare professionals. It is intended to support — not replace — clinical judgement, and must be interpreted alongside your full clinical history, other investigations, and applicable guidelines.
- A result is not a diagnosis and does not by itself decide treatment.
- A "not detected" or normal result does not rule out cancer or a genetic change.
- Not all cancers release enough DNA into blood to be detected.
- The test does not guarantee access to any medicine, its regulatory approval, insurance cover, or that a therapy will work.
- Sample-collection kits are for use by qualified phlebotomists only — not for self-testing or self-sampling.
- Confirmatory testing may be required.
Regulatory status (India). OnKommon's registration of its genomic tests as in-vitro diagnostic (IVD) medical devices with the Central Drugs Standard Control Organisation (CDSCO) is in progress (IVD class pending). Sequencing and variant calling are performed by an accredited laboratory partner (College of American Pathologists — CAP-accredited; ISO 15189) following international guidelines (ACMG/AMP/ASCO/CAP) using a CE-IVD certified variant database. The OnKommon interpretation engine is provided for research and decision-support use. Marketing follows the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 and applicable Indian advertising standards.
Take the next step
Every OnKommon page offers three ways forward. Choose the one that fits where you are today.
Book a free Blueprint Consultation
A no-obligation conversation with our care team, arranged through KPCIRC, to map your situation and the right starting point.
Book now →Free WhatsApp guidance (Signal)
A 4-hour triage reply to your first question, at no cost.
Start WhatsApp triage →